- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 22.07. | Polyrizon Stock Jumps 53% On Positive Preclinical Results For Allergy Blocker | 1 | RTTNews | ||
| 22.07. | Polyrizon-Aktie steigt nach positiven Studiendaten für Allergie-Nasenspray stark an | 4 | Investing.com Deutsch | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 22.07. | Polyrizon stock soars after promising nasal allergy blocker test results | 5 | Investing.com | ||
| 22.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | Polyrizon meldet vielversprechende Ergebnisse für nasalen Allergenblocker | 2 | Investing.com Deutsch | ||
| 22.07. | Polyrizon's nasal allergy blocker shows promising deposition results | 1 | Investing.com | ||
| 22.07. | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | 103 | GlobeNewswire (Europe) | Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 16.07. | Polyrizon Stock Slides After Hours After 52% Surge On Tuesday: Why It Moved | 1 | Benzinga.com | ||
| 15.07. | Polyrizon Shares Jump Over 38% After Securing Nasdaq Listing Extension | 2 | RTTNews | ||
| 15.07. | Polyrizon retains Nasdaq listing following hearings panel | 2 | Seeking Alpha | ||
| 15.07. | Polyrizon secures continued Nasdaq listing after panel hearing | 2 | Investing.com | ||
| 15.07. | Polyrizon sichert sich nach Anhörung Verbleib an der NASDAQ | 2 | Investing.com Deutsch | ||
| 15.07. | Polyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings Panel | 237 | GlobeNewswire (Europe) | Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 15.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.06. | Polyrizon-Direktor Omer Srugo tritt zurück; Vorstand bestätigt unabhängige Mitglieder | 1 | Investing.com Deutsch | ||
| 30.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.06. | Polyrizon Ltd.: Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics | 1 | GlobeNewswire (USA) | ||
| 12.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,770 | -2,35 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 47 auf 52 Euro angehoben und die Einstufung auf "Kaufen" belassen. Qiagen sei zurück auf dem Wachstumspfad, die operative... ► Artikel lesen | |
| NOVAVAX | 5,659 | -0,28 % | Novavax poised to end in red for seventh straight session | ||
| PALATIN TECHNOLOGIES | 0,280 | -3,45 % | Aktionäre von Palatin Technologies stimmen Reverse-Aktiensplit und Vorstandswahlen zu | ||
| INOVIO PHARMACEUTICALS | 1,230 | -0,81 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,360 | 0,00 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| XOMA ROYALTY | 21,200 | -0,93 % | ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction | SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,132 | +159,84 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,320 | -2,52 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds | King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 1,245 | -1,97 % | Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development | SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| VIVUS | - | - | Vivus' Qsymia gains market approval in UAE for obesity treatment | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,611 | -9,49 % | Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption | Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in... ► Artikel lesen | |
| EDESA BIOTECH | 1,840 | -7,54 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results | TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,160 (-12,80 %) liegt der Kurs bei 1,090 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.